BridgeBio Pharma Inc

NASDAQ:BBIO  
52.14
+2.78 (+5.63%)
Products

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for Treatment of Limb-girdle Muscular Dystrophy Type 2i

Published: 09/15/2021 11:42 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (lgmd2i).